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Objective: Dipyrone (Novalgins) is an effective analgesic, antipyretic agent also
with spasmolytic effects on various types of smooth muscles. It has recently been
reported that dipyrone relaxes tracheal smooth muscle of guinea pig. In this present
study, we aimed to investigate whether this and previously reported in vitro results
have any consequences on the respiratory function of normal healthy volunteers and
chronic obstructive pulmonary disease (COPD) patients.
Methods: In this one-centered, non-randomized, non-comparative, open labelled
study, 15 normal healthy volunteers and 15 stable COPD patients, with partially
reversible bronchospasm, diagnosed according to the Global Initiative for Chronic
Obstructive Lung Disease (GOLD) criteria were enrolled in the study at the time they
had any indication of dipyrone use. The spirometric tests were performed by a
portable notebook and Medikro Spiro2000 spirometry programme-software 1.6
version, before 30, 60, 90, and 120min after 20mg/kg of orally dipyrone intake.
Groups were compared with the General Linear Model Repeated Measures analysis of
variance.
Results: None of the spirometric parameters evaluated showed any significant
differences when compared with the baseline values in both groups.
Conclusion: While dipyrone had no bronchodilator effects on either COPD patients
or normal volunteers, it also did not impair the spirometric parameters. Since COPD
is a disease characterized by a progressive and largely irreversible airflow limitation,
dipyrone has no observable bronchodilator effect. However, since dipyrone does notElsevier Ltd. All rights reserved.
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an indication.
& 2005 Elsevier Ltd. All rights reserved.Introduction
Dipyrone is a non-opioid analgesic and antipyretic
agent that has been in clinical use since 1922. It is
used for moderate to severe pain as well as pain
due to smooth muscle spasm or colic pain. The
combination preparations of dipyrone with smooth
muscle relaxing agents, used to treat colic pain in
the past years, were changed to single dipyrone
preparations after the evaluation of the self-
spasmolytic effects of dipyrone.
The spasmolytic effect of dipyrone has been
shown in many in vitro and in vivo experimental
studies. For instance, dipyrone dose dependently
inhibits barium-chloride-induced isolated rat ileum
as well as electrically stimulated, isolated guinea
pig ileum contractions.1 It has also been shown that
dipyrone antagonizes histamine, serotonin and
bradykinin-induced bronchospasm in guinea pigs.2,3
Despite the well-known spasmolytic effect of
dipyrone and the presence of many in vitro, in vivo
studies and clinical trials showing this effect, its
mechanism of action needs to be clarified. In a
previous study, we demonstrated that dipyrone
significantly relaxed pre-contracted tracheal
smooth muscle in guinea pigs.4
There are many randomized, controlled clinical
studies investigating this smooth muscle relaxing
effect on different systems. It has also been shown
that dipyrone reduces the common bile duct and
Oddi sphincter tonus in a dose-dependent manner
as well as efferent urinary tract and urinary vesicle
motility.5–9
The smooth muscle relaxing effect of dipyrone on
the respiratory tract was also shown in clinical
trials, in asthmatic patients. In 1973, Hady re-
ported that premedication with dipyrone eased the
bronchoscopic procedure. Also, dipyrone was found
to increase the gas exchange in the lungs when
given as an analgesic for postoperative pain relief.
In the light of these findings, dipyrone was given to
82 patients suffering from an asthma attack. In all
of the patients, the intravenous injection of
dipyrone interrupted the attack resulting in im-
mediate disappearance of cyanosis and the relief of
chest tightness.10 Resta et al.11 reported two
typical asthmatic cases whose airway obstruction
improved by dipyrone and other non-steroidal anti-
inflammatory drugs (NSAIDs). The patients’ forced
expiratory volume in the first second (FEV1) valuesincreased in 15–30min and bronchodilation was
confirmed by spirometric tests. When dipyrone was
given to the patients, FEV1 values increased up to a
peak of 150% of their baseline values at 60min and
the bronchodilatory effect lasted for 5 h.
Chronic obstructive pulmonary disease (COPD) is
a major cause of chronic morbidity and mortality
throughout the world.12 It is estimated that COPD
will be the third cause of mortality in 2020.13 The
revised Global Initiative for Chronic Obstructive
Lung Disease (GOLD) describes COPD as a disease
state characterized by progressive airflow limita-
tion that is not fully reversible conversely to
asthma and is associated with an abnormal inflam-
matory response of the lungs to noxious particles or
gases.14 The two important points about this
definition is that inflammation is the main mechan-
ism underlying airway abnormalities in COPD
patients, and that smoking is not the only etiolo-
gical factor although COPD is mostly seen in
smokers.15
Despite its bronchodilatory effect on asthmatic
patients, dipyrone has not been studied in COPD
patients. This present study was performed to
investigate whether the in vitro smooth muscle
relaxing-bronchodilatory effects of dipyrone have
any consequences on partially reversible COPD
patients, as we had known that dipyrone can affect
the pre-contracted smooth muscle. We investi-
gated whether COPD patients would benefit from
this smooth muscle relaxing effect when dipyrone
was chosen as the analgesic agent. We also
evaluated its effect on normal healthy volunteers.Material and methods
This one-centered, non-randomized, non-compara-
tive, open-labelled study involving 15 normal
healthy volunteers and 15 COPD patients was
performed in accordance with the Declaration of
Helsinki, with the local laws and regulations
relevant to the use of new and approved ther-
apeutic agents in patients and the International
Conference on Harmonization-Good Clinical Prac-
tice standard. COPD patients were diagnosed
according to the GOLD criteria. The protocol was
approved by the local ethics committee of the
Medical School of Ankara University (October 20,
2003; approval number: 39-990). All volunteers and
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their enrolment in the study.
Subjects and inclusion criteria
Fifteen normal healthy volunteers (seven male,
eight female) were enrolled in the study, as well as
15 (13 male, two female) stable and partially
reversible COPD subjects diagnosed according to
GOLD criteria at the time they had any indication of
dipyrone use. The COPD patients were between 44
and 78 years old, with no history of any adverse
events related to dipyrone. Since we aimed to
investigate whether we could show the smooth
muscle relaxing effects of dipyrone in normal
healthy volunteers or in COPD patients, a rando-
mization schema for the study was not prepared.
Only, partially reversible COPD patients who would
receive dipyrone for any indication were enrolled
into the study, to be observed for 2 h.
Exclusion criteria
Patients with acute exacerbation of COPD and
patients with bronchiectasis, pure emphysema with
no airflow limitation and asthma were not included
in the study. Also, patients were excluded if they
had hypersensitivity to NSAIDs or dipyrone, contra-
indications for the use of dipyrone or any other
NSAIDs (history of peptic ulcer, gastrointestinal
bleeding, elevated liver enzymes, peripheral oede-
ma and acute renal failure), history of nasal
polyposis, angioedema, urticaria, or reactive
bronchospasm following treatment with aspirin or
other NSAIDs. Patients with chronic drug use or drug
abuse or in continuous treatment with prescription
doses of analgesics, NSAIDs, lithium, carbamazepin,
tranquilizers and anticoagulants were also ex-
cluded. Breast-feeding women and women with
proven or assumed pregnancy were not included.
Study design
The spirometric tests were performed by a portable
notebook and the Medikro Spiro 2000 spiro-
metry programme-software 1.6 version. The main
spirometric parameters of tidal volume (TV, l),
frequency rate (FR, l/min), mean volume (MV,
l/min), vital capacity (VC, l), forced vital capacity
(FVC, l), FEV1 (l), FEV%, peak expiratory volume
(PEF, l/s), maximum expiratory flow rate 25%
(MEF25, l/s), maximum expiratory flow rate 50%
(MEF50, l/s), maximum expiratory flow rate 75%
(MEF75, l/s), maximum mid-expiratory flow rate
(MMEF), forced inspiratory vital capacity (FIVC, l),forced inspiratory volume in first second (FIV1, l),
forced inspiratory volume % (FIV%), peak inspira-
tory volume (PIF, l/s), maximum voluntary volume
(MVV, l/min), maximum voluntary volume fre-
quency rate (MVVFR, 1/min), maximum voluntary
volume time (MVVT, s) were measured before, 30,
60, 90 and 120min after dipyrone intake. Dipyrone
was given as an oral suspension at a dose of 20mg/
kg. COPD patients were enrolled in the study at the
time they had any indication for dipyrone use and
they were allowed to get their regular treatment.
Efficacy assessment
The effect of dipyrone on respiratory function in
normal healthy volunteers and in COPD patients
was evaluated by comparing the spirometric para-
meters before and after drug intake. A 12% increase
compared with baseline FEV1 values was considered
as the bronchodilator effect of dipyrone.
Safety assessment
Safety was assessed by monitoring the adverse
events throughout the study period.
Statistical methods
For both groups, the effect of dipyrone was
evaluated with the General Linear Model Repeated
Measures analysis of variance by using SPSS 9.0 for
Windows.Results
All of the normal healthy volunteers completed the
study without any adverse events. An adverse event
characterized by bronchospasm occurred in one
of the COPD patients and the data obtained from
this patient were excluded from further analysis
(Fig. 1).
Demographic data
Seven male (46.6%) and eight female normal
healthy volunteers (age range: 23–59 years), and
13 male (86.6%) and two female COPD patients (age
rage: 44–78 years), were enrolled in the study.
Demographic data of the subjects are tabulated in
Table 1. The mean COPD duration was 8 years.
Sixty-seven percent of the patients with COPD were
smokers with an average of 39 pack-year smoking
history.
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15 normal healthy volunteers (7M, 8F)16 COPD patients (14M, 2F) 
• COPD diagnosed according to the GOLD criteria
• No history of any adverse event reated with 
dipyrone
Enrollment
15 treated with dipyrone
• Spirometric measurement
1 withdrawn
(adverse event n=1)
• Efficacy assessment
• Safety assessment
Run-inVisit
Enrollment
15 treated with dipyrone
• Spirometric measurement
• Efficacy assessment
• Safety assessment
Figure 1 Study outline is figured out briefly.
Table 1 Demographic data of the enrolled subjects.
Group N Gender Age (years7SD) Height (cm7SD) Smokers (%)
Normal healthy volunteers 15 7M, 8F 3273 16575.2 26.6
COPD patients 15 13M, 2F 6472 17074.3 67
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We did not observe any significant change in the
spirometric parameters in either normal healthy
volunteers or COPD patients (Figs. 2 and 3,
respectively).Adverse events
All of the normal healthy volunteers and COPD
patients except one in the COPD group completed
the study without any adverse events during the
study. An adverse event, characterized by dyspnea,
wheezing and cough occurred in one COPD patient
45min after dipyrone intake. The patient recov-
ered totally after treatment with bronchodilators.
The patient was excluded from the study.
The relation between drug exposure and the
bronchospasm was estimated as ‘‘possible’’ when
evaluated by the Naranjo Adverse Drug Reaction
(ADR) scale.23Discussion
Spirometric tests are useful in determining the
airflow limitation degree, in evaluating the re-
sponse to treatment and pursuing the clinical
prognosis.16 Together with the presence of symp-
toms, spirometry helps to stage COPD severity and
can be a guide to specific treatment steps. FEV1
and FEV1/FVC ratio are the most valuable para-
meters in evaluating the obstructive pattern. The
decrease in these parameters is considered as
obstruction in large airways; the lower the percen-
tage predicted FEV1, the worse the subsequent
prognosis. MEF25, MEF2575, MEF75 and MMEF are
the valuable spirometric parameters to evaluate
small airways. A normal value for spirometry
effectively excludes the diagnosis of clinically
relevant COPD. In COPD patients, FVC, FEV1 values
and FEV1/FVC ratios are typically lower than
normal values. Normally, 75–80% of the inspired
air should be expired during the first second of
expiration. COPD patients have less than 80% FEV1
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Figure 2 Main spirometric parameters of normal healthy volunteers. Data are shown as percentage change from
baseline after dipyrone intake+standard error of mean (SEM).
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Figure 3 Main spirometric parameters of COPD patients. Data are shown as percentage change from baseline after
dipyrone intake+standard error of mean (SEM).
S.E. Gulmez et al.832values, and less than 70% FEV1/FVC ratios of the
predicted values.
In controversy to asthma, COPD is an irreversible
or partially reversible obstructive disease. Most
patients’ FEV1 values only increase less than 15% of
the baseline value after one puff of short-acting b2
agonist. The patients showing 15–20% increase in
FEV1 comprise the ‘‘partially reversible’’ subjects.In spite of this increase, FEV1 values of COPD
patients never reach the normal predicted va-
lues.17 Another important point is that, even
though the patients do not show significant FEV1
response to short-acting bronchodilator agonists,
they may benefit symptomatically from long-
acting bronchodilator treatment. Most of the
COPD patients who are given a sufficiently strong
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10% increase in maximal expiratory airflow and a
reduction in hyperinflation and dyspnea, and an
increase in the exercise capacity.18–20
Drugs, which increase FEV1 values or change
other spirometric values by acting on the airway
smooth muscles, are termed as ‘‘bronchodilator
agents’’. They are approved as the main group of
agents for the symptomatic treatment of COPD.
The spasmolytic effect of dipyrone on various
organs such as vessels, urether, and bile duct is a
well-known effect. In a previous study, we demon-
strated that dipyrone significantly relaxed pre-
contracted tracheal smooth muscle in guinea pigs.4
To the best of our knowledge, no randomized
clinical trial evaluating the bronchodilatory effect
of dipyrone in COPD patients has been done. In this
unique study on COPD patients, the effect of
dipyrone on spirometric parameters was examined,
foreseeing that the patients may benefit from its
spasmolytic effect when chosen as an analgesic
alternative. Neither normal healthy volunteers nor
COPD patients showed statistically significant
change on spirometric parameters 30, 60, 90 and
120min after drug intake. According to these
results, we conclude that the smooth muscle
relaxing effect of dipyrone could not be seen in
COPD patients although these patients were par-
tially reversible. The result is not surprising for
normal healthy volunteers since dipyrone has no
effect on basal smooth muscle tonus.
NSAID-induced bronchospasm is a common and
serious problem. A report from MEDSAFE, the New
Zealand Medicines and Medical Devices Safety
Authority, informs that between 8% and 20% of
adult asthmatics experience bronchospasm follow-
ing ingestion of aspirin and other NSAIDs.21 The
administration of NSAIDs to patients with asthma
might result in three different responses—bronch-
oconstriction, bronchodilatation or lack of bronch-
opulmonary action. Also, there are some case
reports about NSAID-induced bronchospasm.22 In
the present study, bronchospasm possibly induced
by dipyrone was observed in one COPD patient
who responded well to the bronchodilators.
The adverse event was diagnosed by clinical
symptoms and spirometric tests. The relation-
ship between drug exposure and the bronchospasm
was estimated as ‘‘possible’’ when evaluated by
the Naranjo ADR scale.23 Using this scale, the
causality estimation did not totally prove that
bronchospasm was induced by dipyrone. Normal
healthy volunteers and other COPD patients did not
exhibit any worsening in spirometric parameters
showing that dipyrone is a safe agent in COPD
patients.Conclusion
No bronchodilator effect of dipyrone in COPD
patients was observed. On the other hand, we
believe that it can be safely used in such patients
when indicated.References
1. Scientific Monograph. Novalgins, Hoechst, 1996.
2. Zicha L, Scheiffarth F, Schmid E, Alms U, Schott G.
Untersuchungen U¨ber Antagonistische Effekte Verschiedener
Antiphlogistica Sowie Muskelrelaxantiken Gegen Histamin
Und Serotonin. Arzneim Forsch 1961;11:598–602.
3. Tu¨rker K, Kiran BK. The antagonistic effect of noramidopyr-
ine methanesulfonate on some pharmacological actions of
the synthetic bradykinin. Arzneim Forsch 1964;14:1318–9.
4. Gulmez SE, Gurdal H, Tulunay FC. The role of phospholipase
C activity in smooth muscle relaxing effect of dipyrone.
Basic and Clinical Pharmacology and Toxicology 2005;
97(suppl. I):100 (Proceedings of the 7th Congress of the
European association for Clinical Pharmacology and Ther-
apeutics).
5. Brandsta¨tter G. Pharmacological pressure reduction in the
human common bile duct. Z Gastroenterol 1983;21:168–74.
6. Brandsta¨tter G, Kratochvil P, Kalhammer R, Schinzel S.
Influence of spasmolytic analgesic on motility of sphincter
oddi. Dig Dis Sci 1996;41:1814–8.
7. Schroth HJ, Garth H, Rupp S, Steinstrasser A. Wirkung Von
Metamizole Auf Die Harnwegs-Motilitat. Fortschr Med
1986;104:378–82.
8. Schroth HJ. Direkte Spasmolytische Wirkung Des Metamizols
Auf Die Glatte Musculatur Der Abfuhrenden Harn-Und
Gallenwege. Therapiewoche 1989;39:1522–5.
9. Schroth HJ, Steinstrasser A, Berberich R, Kloss G. Investiga-
tions on the effect of metamizole on ureteral motility. Brune
K, editor. Agents and actions, supplements, vol. 19. 100
years of pyrazolone drugs. Basel: Birkhauseer Verlag; 1986.
p. 177–88.
10. Hady S. Dipyrone in asthma. Br Med J 1973;1(5855):744.
11. Resta O, Foschino-Barbaro MP, Carnimeo N, Bavoso P, Picca
V. Asthma relieved by acetylsalicylic acid and nonsteroid
anti-inflammatory drugs. Respiration 1984;46:121–7.
12. World Health Organisation. World Health Organisation
Report 2000. Geneva; World Health Organisation; 2001.
13. Lopez AD, Muray CC. The global burden of disease,
1990–2020. Nat Med 1998;4:1241–3.
14. Global Initiative for Chronic Obstructive Lung Disease.
Global strategy for the diagnosis, management, and
prevention of chronic obstructive pulmonary disease.
NHLBI/Who Workshop Report. Bethesda: National Heart,
Lung, and Blood Institute. Update of the Management
Sections, GOLD Website www.goldcopd.com, date updated:
1 July 2003.
15. Pauwels RA. National and international guidelines for COPD:
The need for evidence. Chest 2000;117:20s–2s.
16. Celli BR. The importance of spirometry in COPD and asthma:
effect on approach to management. Chest 2000;117:15s–9s.
17. Pearson MG, Alderslade R, Allen SC, Apps MCP, Barnes G,
Bellamy D, et al. Guidelines for COPD, British Thoracic
Society. Thorax 1997;52(Suppl. 5):S1.
18. Calvarley PM, Burge PS, Spencer S, Andersen JA, Jones PW.
Bronchodilator reversibility testing in chronic obstructive
pulmonary disease. Thorax 2003;58:659–64.
ARTICLE IN PRESS
S.E. Gulmez et al.83419. Global Initiative for Chronic Obstructive Lung Disease. Global
strategy for the diagnosis, management, and prevention of
chronic obstructive pulmonary disease. NHLBI/Who Work-
shop Report. Bethesda: National Heart, Lung, and Blood
Institute, NIH Publication 2001, No 2701, p. 1–100.
20. Barnes PJ. Chronic obstructive pulmonary disease. N Engl
J Med 2003;343:269–80.
21. Sturtevant J. NSAID-induced bronchospasm—a common and
serious problem. A report from MEDSAFE, the New ZealandMedicines and Medical Devices Safety Authority. N Z Dent J
1990;95(421):84.
22. Zikowski D, Hord AH, Haddox JD, Glascock J. Ketorolac-
induced bronchospasm. Anesth Analg 1993;76(2):
417–9.
23. Naranjo CA, Busto U, Sellers EM, Sandor P, Ruiz I, Roberts EA,
et al. A method for estimating the probability of
adverse drug reactions. Clin Pharmacol Ther 1981;30(2):
239–45.
